Related Experiment Video
Updated: Jul 21, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Causal associations of histidine and 12 site-specific cancers: a bidirectional Mendelian randomization study
Xiangju Kong1, Jiaying Yu2, Zhuolin Zhu2
1Department of Gynaecology, First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Abstract:
An increasing number of studies indicate that cancer patients' histidine (HIS) circulating levels have changed. However, the causality between HIS and cancer is still not well established. Thus, to ascertain the causal link between HIS and cancers, we performed a bidirectional Mendelian randomization (MR) analysis. Summary-level data are derived from publicly available genome-wide association studies (GWAS). The causal effects were mainly estimated using the inverse-variance weighted method (IVW). The weighted-median (WM) method and MR-Egger regression were conducted as sensitivity analyses. In the forward-MR, we found malignant neoplasm of respiratory system and intrathoracic organs (OR: 1.020; 95% CI: 1.006-1.035; pIVW = 0.007) genetically associated with circulating HIS. And there was no significant genetic correlation between HIS and another 11 site-specific cancers using IVW method. In the reversed-MR, we did not observe the causal relationship between HIS and 12 site-specific cancers. Our findings help clarify that HIS, as a biomarker for malignant neoplasms of respiratory system and intrathoracic organs, is causal rather than a secondary biomarker of the cancerous progression. The mechanism between histidine and cancer progression deserves further investigation.
More Related Videos
Related Concept Videos
Criteria for Causality: Bradford Hill Criteria - II
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cancer Prevention
Some...
Criteria for Causality: Bradford Hill Criteria - I
Histone Variants at the Centromere
Hazard Ratio
For example, in a clinical trial...

